Beyond Biotech - the podcast from Labiotech
Making waves in cardiovascular disease treatment
May 10, 2024
Robert Blum, CEO of Cytokinetics, discusses the company's aficamten, cardiac myosin inhibitor, and potential treatments for cardiovascular diseases. They cover aficamten's administration, path to commercialization, impact on patients, and future applications. The conversation also explores CK-136 and omecamtiv mecarbil as innovative pharmacological approaches in cardiac muscle activation for heart health.
21:02
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Cytokinetics focuses on innovative muscle activators/inhibitors for cardiac diseases, addressing root causes instead of symptoms.
- AFI Camden, a promising cardiac myosin inhibitor, offers a novel oral treatment approach emphasizing potential for broader applications.
Deep dives
Developing Potential Medicines for Cardiac Muscle Dysfunction
Cytokinetics focuses on discovering muscle activators and inhibitors as treatments for diseases affecting cardiac muscle performance, targeting diseases of muscle weakness and dysfunction. Current cardiovascular treatments often address symptoms rather than directly modulating cardiac muscle proteins, making Cytokinetics' approach innovative for diseases like hypertrophic cardiomyopathy.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
